You are here

MHRP Named a Clinical Trials Unit for NIH HIV/AIDS Clinical Trials Networks

December 18, 2013
MHRP has been selected as a Clinical Trials Unit with four clinical research sites that will receive funding from NIAID to continue HIV vaccine and therapeutics research.

Seven-year award will advance HIV vaccine and therapeutics research at four MHRP sites in Africa

The U.S. Military HIV Research Program, based at the Walter Reed Army Institute of Research, has been selected as a Clinical Trials Unit (CTU) with four clinical research sites that will receive funding from the National Institute of Allergy and Infectious Diseases (NIAID) to continue HIV vaccine and therapeutics research.

MHRP will conduct research as part of the HIV Vaccine Trials Network (HVTN) and AIDS Clincal Trials Group (ACTG), which it has already been a part of since 2009. The HVTN and ACTG are two of five Clinical Trials Networks directed and funded by NIAID that will work together to address NIAID’s HIV/AIDS scientific priorities. 

According to NIAID Director Anthony Fauci, M.D., “These new awards position us to build upon the success of our current HIV/AIDS clinical research infrastructure by creating a broader, more flexible, and more collaborative approach to domestic and global HIV/AIDS research priorities.” 

MHRP Director Col. Nelson Michael will serve as the MHRP CTU’s Principal Investigator and will oversee the following clinical research sites:

  • Kenya Medical Research Institute/Walter Reed Project Clinical Research Center, Kericho, Kenya (ACTG)
  • Moi University Clinical Research Center, Eldoret Kenya (ACTG)
  • National Institute for Medial Research – Mbeya Medical Research Center, Mbeya, Tanzania (HVTN)
  • Polana çanico Health Research and Training Center, National Institute of Health, Maputo, Mozambique (HVTN)